Long-term Follow-up Study of BHC001 for TDT

A Long-term Follow-up Study in Participants Who Received CS-101

NCT06685536 ·Status: ENROLLING_BY_INVITATION

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

NCT06655662 ·Status: RECRUITING ·Phase: PHASE1

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

NCT05773729 ·Status: RECRUITING ·Phase: NA

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

NCT03351829 ·Status: UNKNOWN ·Phase: NA

A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

NCT05015920 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

NCT04390971 ·Status: COMPLETED ·Phase: NA

Thalassemia Treatment Based on the Stem Cell Technology

NCT03222453 ·Status: UNKNOWN ·Phase: NA

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

NCT06065189 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia

NCT06678165 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

NCT05991336 ·Status: RECRUITING

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

NCT05762510 ·Status: RECRUITING ·Phase: EARLY_PHASE1

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

NCT05864170 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

NCT06219239 ·Status: RECRUITING ·Phase: NA

Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia

NCT06734520 ·Status: RECRUITING ·Phase: NA

CS-101 in Patients With β-thalassemia

NCT06328764 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

NCT06024876 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

NCT00171171 ·Status: COMPLETED ·Phase: PHASE3

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

NCT06308159 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

NCT06291961 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

NCT05745532 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

NCT00303329 ·Status: COMPLETED ·Phase: PHASE2

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

NCT06271512 ·Status: RECRUITING

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

NCT05860595 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

β-globin Restored Autologous HSC in β-thalassemia Major Patients

NCT04205435 ·Status: TERMINATED ·Phase: PHASE1/PHASE2